These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 25240597

  • 1. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
    Kim SS, Rait A, Kim E, Pirollo KF, Chang EH.
    Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
    [Abstract] [Full Text] [Related]

  • 2. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
    Kim SS, Rait A, Kim E, Pirollo KF, Nishida M, Farkas N, Dagata JA, Chang EH.
    ACS Nano; 2014 Jun 24; 8(6):5494-514. PubMed ID: 24811110
    [Abstract] [Full Text] [Related]

  • 3. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH.
    Cancer Lett; 2015 Dec 01; 369(1):250-8. PubMed ID: 26325605
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
    Lan Y, Lou J, Hu J, Yu Z, Lyu W, Zhang B.
    Cancer Biol Med; 2020 Feb 15; 17(1):112-131. PubMed ID: 32296580
    [Abstract] [Full Text] [Related]

  • 7. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C, Guo R, Guan F, Ma S, Li M, Wu J, Liu X, Li H, Yang B.
    Sci Rep; 2020 Jun 11; 10(1):9471. PubMed ID: 32528036
    [Abstract] [Full Text] [Related]

  • 8. Neuropilin-1 enhances temozolomide resistance in glioblastoma via the STAT1/p53/p21 axis.
    Huang P, Zhang L, Wang H, Dou C, Ju H, Yue P, Ren J.
    Neuropathology; 2024 Aug 11; 44(4):319-330. PubMed ID: 38448392
    [Abstract] [Full Text] [Related]

  • 9. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA, Burkhart CA, Safina A, Haderski G, Gurova KV, Purmal AA, Gudkov AV, Plunkett RJ.
    Neuro Oncol; 2017 Feb 01; 19(2):186-196. PubMed ID: 27370399
    [Abstract] [Full Text] [Related]

  • 10. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.
    J Clin Invest; 2012 Jan 01; 122(1):253-66. PubMed ID: 22156195
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L, Tang S, Yu Y, Lv Y, Wang A, Yan X, Li N, Sha C, Sun K, Li Y.
    Mol Pharm; 2021 Mar 01; 18(3):915-927. PubMed ID: 33417456
    [Abstract] [Full Text] [Related]

  • 16. WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
    Ma Z, Cai S, Xiong Q, Liu W, Xia H, Zhu Z, Huang Z, Yan X, Wang Q.
    Apoptosis; 2022 Feb 01; 27(1-2):80-89. PubMed ID: 35037107
    [Abstract] [Full Text] [Related]

  • 17. PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
    Liu Q, Xue Y, Chen Q, Chen H, Zhang X, Wang L, Han C, Que S, Lou M, Lan J.
    Oncol Rep; 2017 Nov 01; 38(5):2911-2918. PubMed ID: 29048655
    [Abstract] [Full Text] [Related]

  • 18. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
    Zhao J, Cui X, Zhan Q, Zhang K, Su D, Yang S, Hong B, Wang Q, Ju J, Cheng C, Li C, Wan C, Wang Y, Zhou J, Kang C.
    Theranostics; 2024 Nov 01; 14(7):2835-2855. PubMed ID: 38773970
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN.
    Clin Cancer Res; 2014 Jul 15; 20(14):3730-41. PubMed ID: 24838527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.